ライフサイエンスコーパス: prevention trial

1 re estimated from STAR and the Breast Cancer Prevention Trial.

2 e Mammary Prevention.3 (MAP.3) breast cancer prevention trial.

3 in women with anorexia nervosa in a relapse-prevention trial.

4 ls: the Wheat Bran Fiber Trial and the Polyp Prevention Trial.

5 us women within the Calcium for Preeclampsia Prevention trial.

6 f colorectal cancer, necessitating a primary prevention trial.

7 ovide a rationale for selenium breast cancer prevention trial.

8 ated in a subset of patients in the Fracture Prevention Trial.

9 xt of the recently completed Prostate Cancer Prevention Trial.

10 with the publication of the Prostate Cancer Prevention Trial.

11 sults with the impact of the Prostate Cancer Prevention Trial.

12 the Studies of Left Ventricular Dysfunction Prevention Trial.

13 cancer among all women in the Breast Cancer Prevention Trial.

14 y (HERS), a secondary coronary heart disease prevention trial.

15 5 mg) daily or to placebo in a secondary CHD prevention trial.

16 a-blocker and enalapril was suggested in the Prevention trial.

17 uvant Breast and Bowel Project Breast Cancer Prevention Trial.

18 reduction in the risk of death in the SOLVD Prevention trial.

19 olonoscopy before randomization in the Polyp Prevention Trial.

20 Alzheimer disease (AD) for enrollment in AD prevention trials.

21 ew atopic dermatitis cases for use in future prevention trials.

22 served with antioxidant therapy in secondary prevention trials.

23 tudies and need to be assessed in randomised prevention trials.

24 y at-risk subjects for inclusion in diabetes prevention trials.

25 election of enriched patient populations for prevention trials.

26 e role of fibrillar Abeta imaging in primary prevention trials.

27 pregnancies and power the design of clinical prevention trials.

28 o the statistical power and integrity of HIV prevention trials.

29 lenges of human immunodeficiency virus (HIV) prevention trials.

30 istical power and calculated outcomes of HIV prevention trials.

31 g patients' decisions about participation in prevention trials.

32 cruitment of patients with SLE into clinical prevention trials.

33 ofessional surveillance, or participation in prevention trials.

34 ologic studies and polyp recurrence in polyp-prevention trials.

35 otential for benefit from large-scale cancer prevention trials.

36 of mortality at levels similar to secondary prevention trials.

37 the populations represented in these primary-prevention trials.

38 oxicity for the coxibs in adenoma recurrence prevention trials.

39 cally and methodologically heterogeneous CVD prevention trials.

40 ed by 48% (36-58; p<0.0001) in the tamoxifen prevention trials.

41 er in other animal models or in human cancer prevention trials.

42 ents and death in both primary and secondary prevention trials.

43 ced by both primary prevention and secondary prevention trials.

44 marker for early detection and monitoring of prevention trials.

45 r the success of recently launched secondary prevention trials.

46 coronary heart disease event in the primary prevention trials.

47 ross all trials, and within intervention and prevention trials.

48 increasingly being targeted for AD secondary prevention trials.

49 subjects at high risk of type 1 diabetes to prevention trials.

50 , contributing to lower recruitment rates in prevention trials.

51 ical intervention and be good candidates for prevention trials.

52 es also suggest the feasibility of secondary prevention trials.

53 evaluating the efficacy of intervention and prevention trials.

54 ld be harnessed as an outcome measure for AD prevention trials.

55 isk factors and in research-driven clinical (prevention) trials.

56 meta-analysis of 23 407 patients in primary prevention trials (0.52%): 0.74% with rofecoxib (P =.04

57 ants enrolled in the HIVNET (HIV Network for Prevention Trials) 012 trial.

58 including coronary death or MI) for primary prevention trials (1.5% lower event rate [95% CI, 0.5%-2

59 Strong African American Families randomized prevention trial, 119 right-handed African American indi

60 54 serious vascular events) and 16 secondary prevention trials (17,000 individuals at high average ri

61 ong participants (n = 1,905) in the US Polyp Prevention Trial (1991-1998) on colorectal adenoma recur

62 This study (Calcium for Preeclampsia Prevention Trial, 1992-1995) examines whether nulliparou

63 participants enrolled in the Prostate Cancer Prevention Trial (1993-2003).

64 from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003).

65 from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003).

66 ne in the placebo arm of the Prostate Cancer Prevention Trial (1993-2003).

67 en and risk factors from the Prostate Cancer Prevention Trial, 1993-2003.

68 c hyperplasia (BPH) in 4,770 Prostate Cancer Prevention Trial (1994-2003) placebo-arm participants wh

69 Meanwhile, of 7 prevention trials, 2 suggested possible benefits.

70 In CVD primary and secondary prevention trials, 20-year CRC mortality was reduced amo

71 cipated in the Selenium and Vitamin E Cancer Prevention Trial (2001-2011) with present analyses compl

72 tty acids (SU.FOL.OM3) trial was a secondary prevention trial (2003-2009; n = 2501) in which individu

73 L lower LDL-C level; P = .008) and secondary prevention trials (4.6% lower event rate [95% CI, 2.9%-6

74 Of 18,882 men enrolled in the prevention trial, 9459 were randomly assigned to receive

75 cular death) and major bleeds in six primary prevention trials (95,000 individuals at low average ris

76 men and women participating in the Carotene Prevention Trial, a 2-center chemoprevention trial desig

77 of a randomized controlled trial, the Polyp Prevention Trial, a higher intake of one subclass, flavo

78 participated in the Calcium for Preeclampsia Prevention trial, a randomized study of nulliparous wome

79 ications of Age-Related Macular Degeneration Prevention Trial, aims to evaluate the effects of laser

80 In this large, primary-prevention trial among women, aspirin lowered the risk o

81 Tenofovir/emtricitabine HIV prevention trials among women in Africa have yielded var

82 -SD) follow-up was 34.2+/-14.0 months in the prevention trial and 32.3+/-14.8 months in the treatment

83 , 2012, from among children attending an AOM prevention trial and children visiting local outpatient

84 y of Tamoxifen and Raloxifene) breast cancer prevention trial and in other clinical trials.

85 We also review the recent secondary prevention trials and discuss the options available in t

86 ar diagnostic technique has implications for prevention trials and for the early diagnosis of HCC.

87 ese differences may inform findings from HIV prevention trials and future implementation of antiretro

88 risk, which will inform the design of future prevention trials and guide prognostication.

89 the efficacy of lipid lowering in secondary prevention trials and in reducing ischemic episodes in a

90 bridge the gap between primary and secondary prevention trials and specifically included patients wit

91 Study II, the Selenium and Vitamin E Cancer Prevention Trial, and a European study, Supplementation

92 nseling and testing and enrolled in an HIV-1 prevention trial, and index participants had a baseline

93 rs leading to an international breast cancer prevention trial, and insights into the intricate germli

94 sment, intermediate outcome determination in prevention trials, and regulation of tobacco products.

95 ether Tenofovir (TFV), used vaginally in HIV prevention trials, and Tenofovir alafenamide (TAF), an i

96 targeted communities or clinicians, primary prevention trials, and trials that reported events of no

97 Phase III metastasis-prevention trials are also underway in nonmetastatic CRP

98 rs might be more efficacious, and results of prevention trials are eagerly awaited.

99 Large, well-designed, community-based prevention trials are needed.

100 The first prevention trials are now beginning in patients with gen

101 analyses of 2 randomized controlled primary prevention trials (ASCOT [Anglo-Scandinavian Cardiac Out

102 In the primary prevention trials, aspirin allocation yielded a 12% prop

103 In the secondary prevention trials, aspirin allocation yielded a greater

104 cebo group (n = 9457) in the Prostate Cancer Prevention Trial at 221 US centers were evaluated every

105 and Bowel Project (NSABP) P-1: Breast Cancer Prevention Trial (BCPT) demonstrated the superiority of

106 cancer prevention trials, the Breast Cancer Prevention Trial (BCPT) of tamoxifen and Prostate Cancer

107 ic Adjustment Scale (DAS); the Breast Cancer Prevention Trial (BCPT) Symptom Checklist; the Watts Sex

108 ecular targets for chemoprevention, clinical prevention trials, behavioral prevention research, publi

109 The analyses of two major lung cancer prevention trials, beta-Carotene and Retinol Efficacy Tr

110 spirin versus control in primary (Thrombosis Prevention Trial, British Doctors Aspirin Trial) and sec

111 e chemopreventive agent in the Breast Cancer Prevention Trial, but this result was not replicated in

112 efined, referral into screening programs and prevention trials can be better targeted to reach famili

113 In CVD primary prevention trials, cancer mortality (relative risk [RR],

114 The 2 secondary prevention trials (CARE [Cholesterol And Recurrent Event

115 n progress; the Choroidal Neovascularization Prevention Trial (CNVPT) is the largest pilot study to d

116 3.27; P = 8.4 x 10(-5)) in the Wuhan Smoking Prevention Trial cohort, and they replicated the associa

117 In the primary prevention trial, compared with placebo, pravastatin red

118 s with individual participant data from nine prevention trials comparing four selective oestrogen rec

119 All five randomised prevention trials comparing tamoxifen or raloxifene with

120 trial cancer were increased in all tamoxifen prevention trials (consensus relative risk 2.4 [1.5-4.0]

121 42; 95% CI, 0.29-0.55; P < .001) relative to prevention trials (d = 0.07; 95% CI, -0.13 to 0.28; P =

122 The Prostate Cancer Prevention Trial demonstrated a 25% reduction in period

123 The Prostate Cancer Prevention Trial demonstrated that use of finasteride is

124 al and limitations of using genetic data for prevention trial design.

125 tastatic or advanced cancer; complexities of prevention trial design; a relatively uncharted Food and

126 STAR was a double-blind, randomized phase 3 prevention trial designed to evaluate the relative effic

127 ong screened men enrolled in prostate cancer prevention trials, differences in risk factor estimates

128 ts, aged 55-84 years, in the Prostate Cancer Prevention Trial during 1994-2003.

129 Primary and secondary stroke prevention trials emphasize the importance of aggressive

130 Five primary prevention trials enrolling 1854 patients with NICM were

131 prospective end point in long-term secondary prevention trials evaluating the risks and benefits of a

132 on component of a multisite, primary obesity prevention trial for American Indian schoolchildren.

133 Using evidence from a randomized depression prevention trial for older adults, the authors found tha

134 equisite for enrollment in several secondary prevention trials for AD, yet the precise effect of elev

135 mportant for the designs of future secondary prevention trials for Alzheimer disease.

136 With the onset of prevention trials for individuals at high risk for Alzhe

137 atic Alzheimer's disease to join the ongoing prevention trials, for which mAbs continue to serve as t

138 One large primary prevention trial found that a Mediterranean diet resulte

139 ; 216 total deaths) from exclusively primary prevention trials found a significant reduction in prima

140 Data Synthesis: Two primary prevention trials found no difference in all-cause morta

141 The Stroke Prevention Trial has confirmed that utilization of trans

142 The Prostate Cancer Prevention Trial has provided the first firm evidence th

143 he results of tamoxifen in the Breast Cancer Prevention Trial have made the possibility of chemopreve

144 outcome in clinical trials and toxicity in a prevention trial have shifted focus away from these cycl

145 Observational cohort studies and a secondary prevention trial have shown an inverse association betwe

146 ividuals who are likely to enroll in primary prevention trials have a high socioeconomic status, heal

147 large-scale Alzheimer disease (AD) secondary prevention trials have begun to target individuals at th

148 Primary and secondary prevention trials have extensively examined beta-caroten

149 Although some smaller targeted prevention trials have found that depression risk can be

150 Three fairly large secondary prevention trials have not confirmed the previously repo

151 population-based, Phase III prostate cancer prevention trials have shown a significant benefit for 5

152 Washington Virology Research Clinic) and HIV prevention trials (HIV Prevention Trials Network 039 and

153 In Uganda, the HIV Network for Prevention Trials (HIVNET) 012 study recently demonstrat

154 man Immunodeficiency Virus (HIV) Network for Prevention Trials (HIVNET) 012 trial in Uganda, 6-8 week

155 The HIV Network for Prevention Trials (HIVNET) 012 trial showed that NVP res

156 analyses of large primary and secondary CAD prevention trials, however, clearly demonstrated that re

157 as a secondary risk marker and in secondary prevention trials (ie, with folate/B vitamins) to determ

158 land Coronary Prevention Study was a primary prevention trial in 45- to 64-year-old men with high low

159 's Prevention Initiative Generation Study, a prevention trial in cognitively unimpaired APOE-e4/e4 ho

160 A large multicenter randomized primary prevention trial in heart transplant patients has just b

161 cotland Coronary Prevention Study, a primary prevention trial in hypercholesterolemic men) exhibited

162 minished since the publication of the Stroke Prevention Trial in Sickle Cell Anemia (STOP trial) in 1

163 Although the Stroke Prevention Trial in Sickle Cell Anemia (STOP) demonstrat

164 The Stroke Prevention Trial in Sickle Cell Anemia (STOP) was a rand

165 The Stroke Prevention Trial in Sickle Cell Anemia (STOP) was a rand

166 pants enrolled in the RESPECT study - an HIV prevention trial in Tanzania that used cash awards to in

167 e data from partners participating in an HIV prevention trial in Uganda and Zambia.

168 s a longitudinal, randomized atherosclerosis prevention trial in which repeated dietary counseling ai

169 Secondary prevention trials in AD have already begun in both genet

170 volved a review of the primary and secondary prevention trials in calcineurin inhibitor withdrawal.

171 Prevention trials in preclinical AD require longer and l

172 Prevention trials in SLE face serious challenges, includ

173 the barriers to participation in randomized prevention trials in SLE.

174 inical implications of primary and secondary prevention trials in which amiodarone was used in one of

175 Specifically, in a colon adenoma prevention trial, in all cases tested, individuals who d

176 Key post-myocardial infarction primary prevention trials include the European Myocardial Infarc

177 Several secondary prevention trials, including the Antiarrhythmics Versus

178 uvant Breast and Bowel Project Breast Cancer Prevention Trial indicate that tamoxifen can reduce the

179 The Breast Cancer Prevention Trial is a published, risk-reduction trial th

180 Evidence from prevention trials is now critical to establishing a caus

181 In the SOLVD Prevention Trial, multivariate analyses demonstrated mod

182 Using data from the Prostate Cancer Prevention Trial (n = 5,986), we evaluated prostate-spec

183 Pooled analysis of these secondary prevention trials (n = 256 patients with NICM) indicated

184 established in participants in the Tamoxifen Prevention Trial (National Surgical Adjuvant Breast and

185 Lessons learned from randomized prevention trials need to be implemented with appropriat

186 The HIV Prevention Trials Network (HPTN) 052 study, which showed

187 The HIV Prevention Trials Network (HPTN) 052 trial demonstrated

188 An interim analysis of data from the HIV Prevention Trials Network (HPTN) 052 trial showed that a

189 pproach to estimate HIV incidence in the HIV Prevention Trials Network (HPTN) 064 study.

190 earch Clinic) and HIV prevention trials (HIV Prevention Trials Network 039 and Partners in Prevention

191 mmunodeficiency virus (HIV) acquisition (HIV Prevention Trials Network 039), acyclovir had a smaller

192 The HIV Prevention Trials Network 052 study enrolled serodiscord

193 ssion of HIV infection and data from the HIV Prevention Trials Network 052 study, we projected the co

194 uples and a randomized controlled trial (HIV Prevention Trials Network 052) show that antiretroviral

195 In The HIV Prevention Trials Network 061 study, 155 human immunodef

196 12 clinical research sites of the HIV Prevention Trials Network and AIDS Clinical Trials Group

197 rus type 2 (HSV-2)-seropositive persons (HIV Prevention Trials Network study 039).

198 The recently completed HIV prevention trials network study 052 is a landmark collab

199 ative study, a randomized controlled primary prevention trial of 14 749 postmenopausal asymptomatic w

200 A secondary prevention trial of 400 and 800 IU/day reported a strong

201 ctive by the results of a landmark secondary prevention trial of coronary heart disease (CHD).

202 The WHI included a randomized primary-prevention trial of estrogen plus progestin in 16,608 po

203 Conclusion In this large prevention trial of male physicians, daily multivitamin

204 In this primary prevention trial of nondiabetic individuals with low LDL

205 d that it is feasible to conduct a secondary prevention trial of periodontal therapy in patients who

206 ntion Trial Evaluating Rosuvastatin) primary prevention trial of rosuvastatin 20 mg compared with pla

207 g double-blind, placebo-controlled secondary prevention trial of the benefits and risks of antioxidan

208 However, investigators in the Diabetes Prevention Trial of Type 1 Diabetes (DPT-1) have detecte

209 ata for risk prediction and to enrich future prevention trials of AD.

210 ely disappointing results from several large prevention trials of beta-carotene.

211 primary or secondary coronary heart disease prevention trials of lipid-lowering therapy reported in

212 subgroup analysis of the major CHD secondary prevention trials of lipid-lowering with regard to the b

213 In two large secondary prevention trials of pravastatin, risk reduction was not

214 Prior primary prevention trials of statin therapy that used cholestero

215 Strong African American Families randomized prevention trial or to a control condition.

216 studies (relative risk 1.9 [1.4-2.6] in the prevention trials; p<0.0001) and with raloxifene.

217 le-blind, placebo-controlled, primary cancer prevention trial; participants were Finnish male smokers

218 The 1,015 (24%) Prevention trial patients and 197 (8%) Treatment trial p

219 h reduced mortality remained significant for Prevention trial patients receiving enalapril.

220 with mortality in 4,223 mostly asymptomatic Prevention trial patients, and 2,567 symptomatic Treatme

221 nasteride or placebo) of the Prostate Cancer Prevention Trial (PCPT) and from clinically localized pr

222 To date, the Prostate Cancer Prevention trial (PCPT) is the only reported phase III r

223 rial (BCPT) of tamoxifen and Prostate Cancer Prevention Trial (PCPT) of finasteride, concluded with s

224 Reanalysis of the Prostate Cancer Prevention Trial (PCPT) suggests that high-grade cancer

225 In the Prostate Cancer Prevention Trial (PCPT), finasteride significantly reduc

226 ndomized trials, such as the Prostate Cancer Prevention Trial (PCPT), Reduction by Dutasteride of Pro

227 the finasteride group of the Prostate Cancer Prevention Trial (PCPT), we evaluated the impact of pros

228 te cancer prevention trials (Prostate Cancer Prevention Trial [PCPT] and Selenium and Vitamin E Cance

229 Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which

230 resymptomatic biomarkers now makes secondary prevention trials possible.

231 The Polyp Prevention Trial (PPT) was a multicenter randomized clin

232 Two of the 3 secondary prevention trials presented subgroup estimates for ICD e

233 he placebo arms of two large prostate cancer prevention trials (Prostate Cancer Prevention Trial [PCP

234 MRFIT) was one of the coronary heart disease prevention trials recommended to the National Heart and

235 k of death from all causes in both the SOLVD prevention trial (relative risk, 1.36; 95 percent confid

236 mmunity is initiated in infancy, and primary prevention trials require children at high genetic risk

237 d risk of all-cause mortality across primary prevention trials (RR: 0.94; 95% CI: 0.89, 1.00).

238 umber of incident pregnancies may render HIV prevention trial sample sizes inadequate by as much as 5

239 trial size, duration, and cost--of enriching prevention trial samples by combining clinical informati

240 The Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the Physician's Health Stu

241 The Selenium and Vitamin E Cancer Prevention Trial (SELECT) Eye Endpoints Study was an anc

242 report of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) found no reduction in risk of

243 he large-scale Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed that antioxidants faile

244 er risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) through unknown mechanisms whi

245 cillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical trial o

246 CE) trial, and Selenium and Vitamin E Cancer Prevention Trial (SELECT), have provided practitioners w

247 cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT), plays an integral role in thy

248 en) Selenium and Vitamin E [prostate] Cancer Prevention Trial (SELECT).

249 design of the Selenium and Vitamin E Cancer Prevention Trial (SELECT; testing vitamin E and selenium

250 trolled trial (Selenium and Vitamin E Cancer Prevention Trial [SELECT]) of 35,533 men from 427 partic

251 ial [PCPT] and Selenium and Vitamin E Cancer Prevention Trial [SELECT]) were examined to define incid

252 Analysis of the Polyp Prevention Trial showed an association between an isorha

253 One prospective secondary prevention trial showed benefits that may have resulted

254 Another large, Phase III prostate cancer prevention trial showed no benefit for either selenium o

255 n con Dieta Mediterranea) randomized primary prevention trial showed that a Mediterranean diet enrich

256 The tamoxifen prevention trials showed a 38% (95% CI 28-46; p<0.0001)

257 Primary and secondary prevention trials suggest that statins possess favorable

258 important to consider in upcoming secondary prevention trials targeting CN individuals at high risk

259 ng the possibility of early intervention and prevention trials, targeting MCI and cognitively healthy

260 ed, double-blind, placebo-controlled primary prevention trial testing the effects of beta-carotene an

261 The outcomes of the Prostate Cancer Prevention Trial (testing finasteride) and the design of

262 has been demonstrated by the Prostate Cancer Prevention Trial that a chemoprevention strategy using a

263 aluating Rosuvastatin), a randomized primary prevention trial that compared rosuvastatin treatment to

264 ticle reviews multiple secondary and primary prevention trials that have expanded the indications for

265 INTERPRETATION: In the JUPITER primary prevention trial, the cardiovascular and mortality benef

266 ues in the context of a longitudinal smoking prevention trial, the Midwestern Prevention Project.

267 Data sources were the Breast Cancer Prevention Trial, the Surveillance, Epidemiology, and En

268 Two large-scale, phase III cancer prevention trials, the Breast Cancer Prevention Trial (B

269 Specifically, in the primary prevention trials, the number needed to treat to prevent

270 In both primary and secondary prevention trials, the proportional reductions in the ag

271 a sodium-restricted diet in the Hypertension Prevention Trial, three other large clinical trials repo

272 rrent adenoma during the course of the Polyp Prevention Trial to determine baseline concentrations of

273 te the feasibility of a randomized secondary prevention trial to test whether treatment of periodonta

274 children with ADHD sets the stage for early prevention trials to reduce risk for later depression an

275 consider in deciding about participating in prevention trials, to uncover concerns about SLE trials,

276 alleles among individuals from the Diabetes Prevention Trial-Type 1 (DPT-1) clinical trial, which te

277 cipate in the intervention phase of Diabetes Prevention Trial-Type 1 (DPT-1).

278 n trial progressors to T1D from the Diabetes Prevention Trial-Type 1 with at least one FPIR measureme

279 ng 9,559 participants in the Prostate Cancer Prevention Trial (United States and Canada, 1994-2003).

280 The Prostate Cancer Prevention Trial used the 5alpha-reductase inhibitor fin

281 dividuals is critical for upcoming secondary prevention trials using cognitive outcomes.

282 may be one reason why cardiovascular disease prevention trials using these vitamins have reported con

283 ther the Wheat Bran Fiber Trial or the Polyp Prevention Trial was 0.91 (95% CI: 0.78, 1.06).

284 The estimate from the Prostate Cancer Prevention Trial was 99,441 person-years over the first

285 d to determine eligibility for breast cancer prevention trials was greatly increased relative to prev

286 y outcome-related analysis from a randomized prevention trial, we examined the long-term influence of

287 In the Prostate Cancer Prevention Trial, we randomly assigned 18,882 men 55 yea

288 The overall mortality rates in the prevention trial were 8.1 per 100 person-years for black

289 degree of atypia in 479 patients in a polyp prevention trial were evaluated as predictors of the sam

290 Participants in the double-blind primary prevention trial were randomly assigned to receive 40 mg

291 ND METHODS Raw data from the Prostate Cancer Prevention Trial were used to model chemopreventive trea

292 Randomized controlled primary or secondary prevention trials were considered for inclusion.

293 titis as a secondary outcome, such as asthma prevention trials, were included.

294 se nevirapine from a Ugandan perinatal HIV-1 prevention trial when 496 babies were followed up to age

295 ol study within the Calcium for Preeclampsia Prevention trial, which involved healthy nulliparous wom

296 tate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milli

297 y published results from the Prostate Cancer Prevention Trial: Who are the best candidates for finast

298 Several studies, including a large primary prevention trial with NSAIDs, are still in progress.

299 research is warranted before costly dementia prevention trials with statins are undertaken.

300 Chinese Han population in the Wuhan Smoking Prevention Trial (Wuhan, China, 1998-1999), the authors